A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

NCT06992713 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: H1710 for Injection

Sponsor

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.